Endovascular treatment for intermittent claudication in patients who do not improve with clinical treatment
Nelson Wolosker1, Livio Nakano, Ruben Ayzin Rosoky
1Division of Vascular Surgery, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil. nwolosker@yahoo.com.br
Insights
Endovascular treatment offers lasting relief for intermittent claudication in selected patients. This procedure demonstrates high patency rates and positive long-term outcomes, making it a viable alternative to conservative methods.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Peripheral Artery Disease Management
Background:
- Intermittent claudication significantly impacts quality of life.
- Conservative treatments often yield suboptimal results for severe cases.
- Endovascular approaches offer a minimally invasive option for revascularization.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of endovascular treatment for intermittent claudication.
- To assess outcomes in patients refractory to conservative management.
- To analyze patency rates, walking distance improvement, and morbidity/mortality.
Main Methods:
- A retrospective analysis of 62 patients with intermittent claudication treated between 1992 and 2002.
- Long-term follow-up (mean 76 months, up to 120 months) was conducted.
- Key variables included arterial segment patency, walking distance, and clinical outcomes.
Main Results:
- 94% of patients experienced improved walking ability post-procedure.
- The arterial patency rate was 82% over the follow-up period.
- Late thrombosis occurred in 6 patients, with cardiovascular events contributing to observed mortality.
Conclusions:
- Endovascular treatment provides lasting improvement for selected intermittent claudication patients.
- High patency rates and favorable long-term results support its use.
- This minimally invasive technique is a safe and effective alternative for managing refractory cases.
Purpose:
To study the results including long-term follow-up obtained with endovascular treatment of patients with intermittent claudication who did not experience clinical improvement with conservative treatment.
Methods:
From January 1992 to January 2002, 62 of 1380 patients (4.5%) with intermittent claudication underwent endovascular treatment and were followed up for up to 120 months (mean 76 months). The variables analyzed were the functioning of the arterial segment undergoing the endovascular procedure, the evolution of the maximum walking distance, and incidence of related morbidity and mortality.
Results:
Fifty-two patients (84%) experienced no walking limitation after the procedure, and 6 patients (10%) improved but still exhibited some degree of limitation, for a total improved outcome of 94%. The patency rate was 82%. There was no intraoperative mortality. One primary failure and one immediate thrombosis occurred, and both were surgically corrected. Thrombosis of the treated artery occurred in 6 patients 12, 16, 25, 29, 62, and 66 months after the procedure. These patients started to experience intermittent claudication with a walking distance to onset that was similar to their presurgical distance to onset. During follow-up, a mortality rate of 12.9% (8 patients) was observed, 6 due to myocardial infarctions and 2 due cerebral infarction. Three patients underwent coronary bypasses 22, 36, and 55 months after the endovascular surgery, and 2 patients underwent coronary angioplasty after 6 and 26 months. The mean follow up period was 76 months (range 0-120 months).
Conclusion:
This study shows that endovascular treatment of intermittent claudication brought about a lasting regression of the ischemic conditions in a significant number of patients, with excellent patency rates. It was concluded that this is a good alternative for selected patients, with low rates of complications and positive long-term results.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Venous Thrombosis III: Interprofessional Care
Aneurysm III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
